|
KR101939710B1
(ko)
|
2011-12-21 |
2019-01-17 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
UY34993A
(es)
|
2012-08-28 |
2014-02-28 |
Janssen R & D Ireland |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
|
|
JO3583B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
HRP20181863T1
(hr)
|
2013-05-17 |
2018-12-28 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
NO3024819T3
(enExample)
|
2013-07-25 |
2018-07-21 |
|
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
WO2015120178A1
(en)
|
2014-02-05 |
2015-08-13 |
Novira Therapeutics, Inc. |
Combination therapy for treatment of hbv infections
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
CN117865872A
(zh)
|
2014-12-18 |
2024-04-12 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
HK1247147A1
(zh)
|
2015-03-19 |
2018-09-21 |
诺维拉治疗公司 |
氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
|
|
KR20180012853A
(ko)
|
2015-06-16 |
2018-02-06 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
AU2016301196B2
(en)
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
|
CN108430971A
(zh)
|
2015-09-29 |
2018-08-21 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
DK3355884T3
(da)
|
2015-10-01 |
2021-08-02 |
Olema Pharmaceuticals Inc |
Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
|
|
CA3011391C
(en)
|
2015-11-12 |
2021-02-09 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
ES2935125T3
(es)
|
2015-12-09 |
2023-03-01 |
Univ Illinois |
Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
|
|
HK1244808A1
(zh)
|
2015-12-22 |
2018-08-17 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物、其制备方法及其在医药上的应用
|
|
KR102479822B1
(ko)
|
2016-02-05 |
2022-12-21 |
인벤티스바이오 엘엘씨 |
선택적 에스트로겐 수용체 분해제 및 이들의 용도
|
|
US20190142811A1
(en)
*
|
2016-04-01 |
2019-05-16 |
Zeno Royalties & Milestones, LLC |
Estrogen receptor modulators
|
|
KR20180129943A
(ko)
|
2016-04-15 |
2018-12-05 |
노비라 테라퓨틱스, 인코포레이티드 |
캡시드 조립 억제제를 포함하는 배합물 및 방법
|
|
US10125135B2
(en)
|
2016-04-20 |
2018-11-13 |
Astrazeneca Ab |
Chemical compounds
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
US20170362228A1
(en)
|
2016-06-16 |
2017-12-21 |
Genentech, Inc. |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
WO2017216279A1
(en)
*
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
CN109415361B
(zh)
*
|
2016-06-29 |
2022-03-08 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
BR112018077136A2
(pt)
|
2016-07-01 |
2019-04-30 |
G1 Therapeutics, Inc. |
composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
|
|
US10149839B2
(en)
|
2016-07-25 |
2018-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
JOP20190090B1
(ar)
|
2016-10-24 |
2023-03-28 |
Astrazeneca Ab |
مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
|
|
AR110728A1
(es)
|
2017-01-06 |
2019-04-24 |
G1 Therapeutics Inc |
Terapia combinada para el tratamiento del cáncer
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
EP3689873B1
(en)
*
|
2017-01-30 |
2022-09-14 |
Astrazeneca AB |
Estrogen receptor modulators
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
TW201835064A
(zh)
|
2017-02-10 |
2018-10-01 |
美商G1治療公司 |
苯并噻吩雌激素受體調節劑
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN110536888B
(zh)
*
|
2017-06-20 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
CA3067873A1
(en)
|
2017-06-29 |
2019-01-03 |
G1 Therapeutics, Inc. |
Morphic forms of g1t38 and methods of manufacture thereof
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
*
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
EP3755683A1
(en)
*
|
2018-02-23 |
2020-12-30 |
Center for Intelligent Research in Crystal Engineering, S.L. |
Cocrystals of ubiquinol and compositions comprising them
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
SG11202011135WA
(en)
|
2018-05-14 |
2020-12-30 |
Nuvation Bio Inc |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
TWI915239B
(zh)
|
2018-06-21 |
2026-02-11 |
瑞士商赫孚孟拉羅股份公司 |
3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
|
|
MA53105A
(fr)
|
2018-07-03 |
2021-05-12 |
Univ Illinois |
Activateurs de la réponse à une protéine non dépliée
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
CN113164467B
(zh)
*
|
2018-12-24 |
2023-12-26 |
益方生物科技(上海)股份有限公司 |
选择性雌激素受体降解剂的新型盐
|
|
US11096931B2
(en)
|
2019-02-22 |
2021-08-24 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
US11491148B2
(en)
|
2019-05-06 |
2022-11-08 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
US11826430B2
(en)
*
|
2019-05-14 |
2023-11-28 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
EP3993787A4
(en)
|
2019-08-06 |
2023-07-12 |
Recurium IP Holdings, LLC |
Estrogen receptor modulators for treating mutants
|
|
US20220389006A1
(en)
*
|
2019-11-04 |
2022-12-08 |
Recurium Ip Holdings, Llc |
Salts and forms of an estrogen receptor modulator
|
|
US11952349B2
(en)
|
2019-11-13 |
2024-04-09 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
MX2022008091A
(es)
|
2020-01-10 |
2022-07-11 |
Jiangsu Hengrui Medicine Co |
Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina.
|
|
IL295709A
(en)
|
2020-03-05 |
2022-10-01 |
C4 Therapeutics Inc |
Compounds for targeted degradation of brd9
|
|
MX2022010425A
(es)
|
2020-03-06 |
2022-09-07 |
Olema Pharmaceuticals Inc |
Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
|
|
JP7712955B2
(ja)
|
2020-04-24 |
2025-07-24 |
アストラゼネカ・アクチエボラーグ |
癌の治療のための投薬レジメン
|
|
MX2022013258A
(es)
|
2020-04-24 |
2022-11-14 |
Astrazeneca Ab |
Formulaciones farmaceuticas.
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
WO2022029799A1
(en)
*
|
2020-08-05 |
2022-02-10 |
Aizant Drug Research Solutions Private Limited |
Solid dosage forms of palbociclib
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
WO2022109395A2
(en)
|
2020-11-23 |
2022-05-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
JP2024502270A
(ja)
*
|
2020-12-23 |
2024-01-18 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
エストロゲン受容体調節薬
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
JP2024523839A
(ja)
|
2021-06-08 |
2024-07-02 |
シーフォー セラピューティクス， インコーポレイテッド |
突然変異体ｂｒａｆを分解する療法薬
|
|
IL309986A
(en)
*
|
2021-07-08 |
2024-03-01 |
Olema Pharmaceuticals Inc |
Methods of treating estrogen receptor-associated diseases
|
|
EP4368624A4
(en)
|
2021-07-09 |
2024-12-18 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
SALT TYPES OF A TRICYCLIC TETRAHYDROISOQUINOLINE DERIVATIVE
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
KR20250055538A
(ko)
|
2022-08-03 |
2025-04-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret 단백질을 조정하기 위한 화합물
|
|
CN120569388A
(zh)
|
2022-11-04 |
2025-08-29 |
百时美施贵宝公司 |
Ret-ldd蛋白降解剂
|
|
JP2025540906A
(ja)
|
2022-11-04 |
2025-12-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｒｅｔ－ｌｄｄタンパク質阻害剤
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
AU2024310341A1
(en)
|
2023-06-30 |
2026-02-12 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
US12558428B2
(en)
|
2024-03-08 |
2026-02-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|